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Background: Cisplatin-radiotherapy is a preferred standard for locally advanced, head and neck squamous cell carcinoma
(HNSCC). However, the cisplatin-attributable survival benefit is small and toxicity substantial. A biomarker of cisplatin resistance
could guide treatment selection and spare morbidity. The ERCC1-XPF nuclease is critical to DNA repair pathways resolving
cisplatin-induced lesions.
Methods: In a phase II trial, patients with untreated Stage III-IVb HNSCC were randomised to cisplatin-radiotherapy with/without
erlotinib. Archived primary tumours were available from 90 of 204 patients for this planned substudy. Semi-quantitative ERCC1
protein expression (H-score) was determined using the FL297, 4F9, and 8F1 antibodies. The primary analysis evaluated the
relationship between continuous ERCC1 protein expression and progression-free survival (PFS). Secondary analyses included two
pre-specified ERCC1 cutpoints and performance in HPV-associated disease.
Results: Higher ERCC1 expression was associated with inferior PFS, as measured by the specific antibodies FL297 (HR¼ 2.5, 95%
CI¼ 1.1–5.9, P¼ 0.03) and 4F9 (HR¼ 3.0, 95% CI¼ 1.2–7.8, P¼ 0.02). Patients with increased vs decreased/normal ERCC1
expression experienced inferior PFS (HR¼ 4.8 for FL297, P¼ 0.003; HR¼ 5.5 for 4F9, P¼ 0.007). This threshold remained
prognostic in HPV-associated disease.
Conclusion: ERCC1-XPF protein expression by the specific FL297 and 4F9 antibodies is prognostic in patients undergoing
definitive cisplatin-radiotherapy for HNSCC, irrespective of HPV status.
Head and neck cancer is the sixth leading cancer worldwide, with
600 000 cases anticipated in 2012 (Kamangar et al, 2006; Siegel
et al, 2012). Head and neck squamous cell carcinoma (HNSCC)
accounts for more than 90% of incident cases. Despite advances in
surgical and radiotherapy techniques, as well as integration of
chemotherapy into multimodality treatment paradigms for
HNSCC, 5-year overall survival (OS) is 40–60% and has increased
only incrementally since 1990 (Jemal et al, 2010). The current
standard of care for primary nonsurgical management of locally
advanced HNSCC is concurrent cisplatin-radiotherapy, which
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significantly improved OS, progression-free survival (PFS), and
locoregional control (LRC) compared with radiotherapy alone in
the sentinel clinical trial, Intergroup 0126 (Adelstein et al, 2003).
Similarly, concurrent cisplatin is indicated in the high-risk
adjuvant setting (Bernier et al, 2004; Cooper et al, 2004). Although
local control and overall survival (OS) are improved with
concurrent platinum-based chemoradiotherapy, disappointing
local and distant failure rates of 50% and 15%, respectively,
coupled with an absolute survival benefit of only 6.5% compared
with radiotherapy alone suggest that only a subgroup benefits
(Pignon et al, 2009). Given the considerable toxicities of cisplatin
including nausea, hearing loss, nephrotoxicity, myelosuppression,
and exacerbation of radiation effects such as mucositis and
dysphagia (Henk, 1997; Adelstein et al, 2003; Trotti et al, 2003),
the capacity to pre-select patients who would benefit is paramount.
Cisplatin [cis-diamminedichloroplatinum(II)] reacts with DNA
to form adducts affecting either a single strand (the monoadduct or
intrastrand crosslink) or two strands (the interstrand crosslink or
ICL). These DNA lesions are, respectively, repaired by nucleotide
excision repair (NER) or the distinct mechanism of ICL repair
(Palom et al, 2002). ERCC1-XPF is a bipartite, structure-specific
nuclease critical for both NER and ICL repair (De Silva et al, 2000).
As such, ERCC1-XPF is the only enzyme required for removal of
all cisplatin-induced DNA lesions. ERCC1 and XPF heterodimerise
and stabilise each other in vivo; thus, expression levels tightly
correlate (Niedernhofer et al, 2006), indicating that either protein
may serve as a candidate biomarker for DNA repair capacity
following cisplatin exposure.
In 2006, the International Adjuvant Lung Trial (IALT) bio-
investigator group retrospectively reported that low vs high
tumoural ERCC1 protein expression significantly predicted benefit
from adjuvant cisplatin doublet chemotherapy in operable non-
small cell lung cancer (NSCLC) (Olaussen et al, 2006). Robust
results from a large randomised phase III trial generated intense
interest in further development of ERCC1 as a predictive
biomarker for platinum benefit. Initial enthusiasm was tempered
by recognition that the antibody used in IALT, 8F1, was not
specific for ERCC1 (Niedernhofer et al, 2007). Although 8F1 is able
to immunoprecipitate ERCC1-XPF, it also tags a spurious 45 kDa
band on immunoblotting (Bhagwat et al, 2009), a cross-reaction
that results in ERCC1-XPF-deficient cells being incorrectly
characterised as having ERCC1-XPF expression. The second
antigen recognised by 8F1 may represent the unrelated nuclear
membrane protein, PCYT1a, which shares a common epitope with
ERCC1 (Ma et al, 2012). More troubling, the performance of 8F1
may have drifted over time; the IALT bio-investigator group
recently controverted their original findings when unable to
validate 8F1 in a second cohort, nor reproduce their findings in
the original IALT specimens (Friboulet et al, 2013).
Early reports in HNSCC also noted an association between high
ERCC1 expression and inferior clinical outcomes after platinum-
based therapy (Handra-Luca et al, 2007; Jun et al, 2008; Fountzilas
et al, 2009; Chiu et al, 2011). However, results from these small,
retrospective studies were inconsistently validated by others,
possibly because the nonspecific 8F1 antibody was used (Koh
et al, 2009; Hayes et al, 2011; Moeller et al, 2011). Two recent
reports, using specific antibodies for ERCC1 or XPF, found that
higher expression was associated with inferior PFS after cisplatin-
radiotherapy (Hao et al, 2011; Vaezi et al, 2011b). Preliminary
findings suggested that ERCC1 expression may be of superior
prognostic value in patients with tumours negative for human
papillomavirus (HPV) (Hao et al, 2011). These hypothesis-
generating reports presented retrospective findings from patients
treated in the routine clinical setting. Here, we present a planned
analysis of tumoural ERCC1 expression from a randomised, phase
II clinical trial of cisplatin-radiotherapy with or without erlotinib in
locally advanced HNSCC (Martins et al, 2013a). We investigated
the prognostic relationship of 8F1 and two ERCC1-specific
antibodies to PFS in a cohort treated homogeneously with
cisplatin-radiotherapy, and followed prospectively for clinical
outcomes. We further explored concordance of the three
antibodies and performance in patients with HPV-associated
HNSCC.
MATERIALS AND METHODS
Patients and specimens. A total of 204 patients were treated in
the randomised phase II trial (ClinicalTrials.gov Registration:
NCT00410826) between December 2006 and October 2011, with
105 patients enrolled in the standard arm (cisplatin-radiation) and
99 patients enrolled in the experimental arm (cisplatin-radiation
with erlotinib 150 mg daily; Martins et al, 2013a). Cisplatin was
administered at 100 mg m 2 on days 1, 22, and 43 of radiotherapy
to both patient groups. Radiation dose was 70 Gy in 35 fractions
over 7 weeks with 3D conformal techniques or its equivalent with
intensity modulated radiotherapy. Randomisation was stratified by
center and degree of nodal involvement (N0/1 vs N2/3). The
primary end point was complete response rate (CRR) following
chemoradiotherapy; secondary endpoints were PFS and OS. For
this biomarker study, formalin-fixed paraffin-embedded (FFPE)
pre-treatment primary tumour tissue was analysed when patients
provided consent and tissue was available.
ERCC1 evaluation. Pre-cut slides sectioned at 4m thickness
were autostained using standard immunohistochemistry (IHC)
protocols on Leica Bond III immunostainers (Leica Microsystems
Inc, Buffalo Grove, IL, USA) according to the manufacturer’s
operating instructions. Three distinct ERCC1 antibodies were used,
including an 8F1 monoclonal antibody (1 : 400 dilution, Neomarkers,
Kalamazoo, MI, USA), a 4F9 monoclonal antibody (1 : 200
dilution, OriGene, Rockville, MD, USA), and an FL297 polyclonal
antibody (1 : 50 dilution, Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA). Antigen retrieval was effected by heat-induced
epitope retrieval (HIER) using Tris-EDTA for 20 min. The slides
were then incubated at room temperature for 15 min (8F1 and 4F9)
or 60 min (FL297). Four micron-thick sections of normal and
neoplastic lung tissue were included as external positive controls.
Basal epithelial cells in normal tissue adjacent to each tumour
served as an internal positive control. At the time of ERCC1
staining, the ultra-specificity of 4F9 had not yet been reported in
the published literature (Ma et al, 2012). Thus, the 4F9 antibody
was evaluated for specificity against ERCC1 by western blot,
immunofluorescence, and IHC techniques in normal and XPF-
ERCC1-deficient human fibroblasts as previously described
(Niedernhofer et al, 2007; Bhagwat et al, 2009). XP2YO cells were
used because they have only a trace amount of ERCC1 and are an
accepted reagent to assess antibody specificity for ERCC1
(Niedernhofer et al, 2007; Bhagwat et al, 2009). D10 and 8F1
were used as ERCC1-specific and non-specific control antibodies,
respectively, as previously characterised (Bhagwat et al, 2009).
A single pathologist (MA) blinded to outcomes evaluated all
IHC staining under a light microscope at a magnification of  400.
A semi-quantitative H-score (expression x intensity) was calculated
for ERCC1 expression. To overcome variance in pre-analytic
processing including differences in cold ischemia time, formalin
fixation, processor protocols, and storage that likely differed
among sites, staining intensity was assigned with reference to an
internal control. Specifically, the staining intensity of the nuclei of
non-neoplastic basal epithelial cells (internal control, present in all
samples) was designated normal or 2þ , as previously described
(Handra-Luca et al, 2007). The staining intensity of tumour cell
nuclei was compared with the internal control with 0 representing
no staining, 1þ representing decreased, 2þ representing
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equivalent, and 3þ representing increased. Fifty neoplastic cells
from three separate areas of each slide were counted. The
percentage of cells staining for ERCC1 (see Figure 1) was assigned
a weighted expression score as described (None¼ 0, 1–9%¼ 0.1,
10–49%¼ 0.5, and 50–100%¼ 1) (Olaussen et al, 2006; Handra-
Luca et al, 2007). In tumours with heterogeneous ERCC1 staining,
multiple representative areas were scored; staining intensity was
assigned as a weighted sum rounded to the nearest quartile. For
example, if 60% of cells stained for ERCC1 and the proportion of
cells staining 3þ vs 2þ was 70 : 30, the H-score was calculated as
weighted expression (1)  weighted intensity (2.75)¼ 2.75.
Although previous studies commonly used the H-score median
split to define increased vs decreased ERCC1 expression (Handra-
Luca et al, 2007; Hao et al, 2011), the use of an internal control
allowed pre-definition of three categorical H-scores potentially
applicable across study populations: ‘decreased expression’
(H-scorep1.5), ‘normal expression’ (1.5oH-scoreo2.5), and
‘increased expression’ (H-scoreX2.5). These categorical thresholds
were defined empirically: 1.5 corresponded to the mathematical
point where the majority of tumour cells had decreased ERCC1
staining and, similarly, 2.5 corresponded to the mathematical point




Figure 1. Representative 3þ ERCC1 Staining for FL297, 4F9, and 8F1. Representative ERCC1 stains are presented for consecutive sections of a
p16-negative hypopharynx tumour. Note that staining intensity cannot be compared among antibodies as it is referenced to an internal control
designated 2þ (arrow in box C). (A) H&E stained invasive squamous cell carcinoma at  20 magnification. (B) Negative control; tissue shows lack
of non-specific ERCC1 staining. (C) 3þ ERCC1 staining for 4F9. (D) 3þ ERCC1 staining for 8F1. (E) 3þ ERCC1 staining for FL297.
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p16 evaluation. Overexpression of the p16 cell cycle protein is
the accepted surrogate for HPV infection, an established
prognostic biomarker in oropharyngeal HNSCC (Ang et al,
2010). To assess p16, pre-cut slides sectioned at 4 m thickness
were auto-stained using standard immunohistochemistry (IHC)
protocols on Leica Bond III immunostainers according to the
manufacturer’s operating instructions. Antigen retrieval was
effected by HIER using Tris-EDTA for 20 min. The slides were
then incubated at room temperature for 30 min with an undiluted
CINTec p16 antibody (MTM Labs AG, Ventana Medical Systems
Inc., Tucson, AZ, USA). Four micron-thick sections of cervical
intraepithelial neoplasia II tissue were included as external
positive controls.
In accordance with standard grading criteria, p16-positivity
was defined as tumours with X70% of neoplastic cells
demonstrating strong and diffuse nuclear and cytoplasmic
staining (Jordan et al, 2012). All available tumours were
stained for p16, regardless of anatomic site. However,
only p-16-positive oropharynx tumours were classified as
HPV-associated.
Statistical analysis. The sample size for this analysis was
determined by tissue availability. Assuming an exponential survival
function and median PFS of 18 months for patients with higher
risk of relapse/death (Ang et al, 2010), a study accruing 24 patients
per year for 3.75 years (n¼ 90), with an additional 6 months of
follow-up, would have B91% power for a two-sided test to detect a
hazard ratio of 3.0, if 50%–67% of patients have a lower risk of
relapse. Power would be 82% to detect a hazard ratio of 2.5.
The primary statistical analysis evaluated the association
between ERCC1 expression and PFS by Cox proportional hazards
regression, stratified by randomisation strata and controlling for
treatment arm. Formal hypothesis testing was planned only for
the specific FL297 and 4F9 antibodies, to limit overall Type I
error, with alpha set at 0.05. Although the primary statistical
analysis considered ERCC1 H-scores as continuous variables, the
three pre-specified ERCC1 expression categories were used for
graphical display. Categorical ERCC1 expression also permitted
preliminary investigation of two pre-defined cutpoints (decreased
vs normal/increased; decreased/normal vs increased), for future
investigation of ERCC1 expression as an integral prospective
biomarker. To minimise false discovery, no other cutpoints
were tested.
Agreement among ERCC1 expression assays was assessed
using Bland-Altman plots and summarised by the concordance
correlation coefficient, using the SAS %CCC macro (Barnhart
et al, 2002; Crawford et al, 2007). Associations between ERCC1
and p16 expression and other prognostic factors, and their
independent or combined associations with PFS, were also
explored. A Wilcoxon rank-sum test was used to evaluate ERCC1
expression in association with p16 status. Additional comparisons
between categorical variables were conducted using w2-tests of
association. Kaplan–Meier curves were used for graphical
illustrations of associations between PFS and markers. Statistical
tests were two-sided, and analyses were conducted using the SAS/
STAT software version 9.3 (SAS Institute, Inc., Cary, NC, USA)
and R version 2.15.0 (R Foundation for Statistical Computing,
Vienna, Austria).
RESULTS
Clinical outcomes. In the parent trial, clinical outcomes did not
differ according to the treatment arm, including the primary end
point of CRR and the secondary end point of PFS (Martins et al,
2013b). The CRR according to standardised protocol criteria was
40% vs 52% on the standard vs experimental arm (P¼ 0.08).
With a median follow-up of 26 months, there was no difference in
PFS (HR¼ 0.9, P¼ 0.71). The primary biomarker analysis there-
fore did not control for treatment-by-marker interactions, which
were not statistically significant and had little effect on parameter
estimates or inference for ERCC1 effects.
Specificity of 4F9. The 4F9 monoclonal antibody was found to be
specific for ERCC1. By western blot on XP2YO cell lysates, or by
immunofluorescence and IHC on XP2YO cells, 4F9 demonstrated
only background signal in the ERCC1-XPF-deficient cells
(Figure 2).
ERCC1 expression. Sufficient analysable tissue was submitted
from 90 patients consenting to optional tissue correlatives. Table 1
summarises the characteristics of patients with and without
available tissue. Tissue assessment did not differ by treatment
arm, sex, smoking status, or other demographic characteristics.
There was a nonsignificant tendency for tissue to be available for
patients with higher T-stage (P¼ 0.09), and patients classified with
oral cavity or overlapping primary site were less likely to have
tissue available as compared with pharyngeal or laryngeal sites
(P¼ 0.009).
We evaluated marker prevalence for 8F1 and two specific anti-
ERCC1 antibodies, FL297 and 4F9 (Table 2). IHC was performed
for all three ERCC1 antibodies in 88 of 90 tumours, limited by
tissue availability. The majority of tumours was p16 positive,
including 50 oropharyngeal (50/64, 78%) and 6 non-oropharyngeal
tumours (6/26, 23%). Approximately half of tumours demon-
strated increased ERCC1 expression, relative to internal control,
with each antibody. The 4F9 and FL297 assays showed good
agreement with a concordance correlation coefficient (CCC) of
0.88 (95% CI 0.82–0.92). The 8F1 antibody demonstrated a higher
percentage of tumours with decreased ERCC1 staining and had
modest concordance with the 4F9 (CCC¼ 0.53, 95% CI 0.37–0.66)
and FL297 (CCC¼ 0.44, 95% CI 0.26–0.59) antibodies. Concor-
dance of ERCC1 assays is displayed by Bland–Altman plots in
Figure 3.
ERCC1 and PFS. Table 3A presents the primary results from Cox
proportional hazards models, examining the association between
the three ERCC1 assays and PFS, stratified by randomisation strata
and controlling for treatment arm. Higher ERCC1 expression was
associated with a greater hazard of progression or death, as
measured using the FL297 (HR¼ 2.5, 95% CI 1.1–5.9) and 4F9
assays (HR¼ 3.0, 95% CI 1.2–7.8), but not the 8F1 assay
(HR¼ 1.4, 95% CI 0.8–2.5). To graphically illustrate the associa-
tions between ERCC1 expression and PFS, Kaplan–Meier plots
using three pre-specified expression categories (decreased, normal,
increased) are presented in Figure 4.
Exploratory analysis of two pre-specified categorical cutpoints
for ERCC1 expression (decreased vs normal/increased or
decreased/normal vs increased), as measured by the specific
antibodies FL297 and 4F9, indicated that patients with increased
tumoural expression were at significantly greater risk for progres-
sion or death compared with patients with decreased/normal
expression (HR¼ 4.8 for increased FL297 ERCC1 expression,
P¼ 0.003; HR¼ 5.5 for increased 4F9 expression, P¼ 0.007;
Table 3B).
ERCC1 and known prognostic factors. Overexpression of the
p16 cell cycle protein, a consequence of the degradation of
retinoblastoma by the HPV E7 oncoprotein, is indicative of
biologically relevant HPV infection and serves as a prognostic
biomarker in oropharyngeal HNSCC (Ang et al, 2010). Associa-
tions between p16 status and ERCC1 were therefore analysed by
the Wilcoxon rank-sum test for FL297 and 4F9 (Figure 5). For both
antibodies, there was a significant trend for ERCC1 expression to
be higher in p16-negative than in p16-positive tumours, although
all categorical expression levels were observed in both. In the 33
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p16-negative tumours, the proportion of (decreased/normal/
increased) ERCC1(FL297) expression was 12%, 27%, 61%,
compared with 15%, 49%, 36% in 55 p16-positive tumours.
Proportions were similar for 4F9. Associations between the two
specific ERCC1 antibodies and PFS were not altered substantially
by controlling for p16 status (p16-positive oropharyngeal tumour
vs other; Table 3C). Data were too sparse to estimate an ERCC1-
by-p16 interaction term.
The primary analysis (Table 3A) accounted for N-stage, a
known prognostic factor, as part of randomisation strata. Another
known prognostic factor, T-stage (T1/2 vs T3/4), did not
contribute to predicting PFS in secondary models accounting
for ERCC1 assays and randomisation stratum (models not
shown).
An exploratory analysis of PFS by ERCC1 restricted to patients
with p16-positive oropharyngeal tumours was performed to isolate
whether ERCC1 may be prognostic in HPV-associated HNSCC as
currently defined. Supplementary Figure 1 suggests that ERCC1 as




































Figure 2. The 4F9 antibody is specific for ERCC1. Specificity of 4F9 is assessed in human skin fibroblasts isolated from either a normal individual
(WT) or an individual with a mutation in XPF causing near-undetectable ERCC1 (XP2YO). (A) 4F9 is specific by western blot. Only a trace amount of
ERCC1 is detected in XP2YO cells with either 4F9 or the specific anti-ERCC1 antibody D-10. In contrast, the non-specific 8F1 antibody recognises
an additional band migrating slightly slower than ERCC1, present both in WT and ERCC1 deficient cells (arrows). Tubulin (loading control). (B) 4F9
is specific by immunofluorescence. Only background nuclear signal is observed in ERCC1-deficient cells either with 4F9 (white asterisks) or with the
antibody D-10 while nuclear staining is readily observable in WT cells. In contrast, the nuclear signal persists in ERCC1 deficient cells when 8F1 is
used, confirming the lack of specificity of this antibody. ERCC1 antibodies (red); DNA stain DAPI (blue). (C) Quantitation of average nuclear
fluorescence intensity represented by boxplot; p (paired t-test); * indicates statistical significance. (D) 4F9 is specific by immunohistochemistry
performed on formalin-fixed paraffin-embedded cells. Only background staining is observed in ERCC1-deficient cells (black asterisks).
4F9 (brown); haematoxylin counterstain (blue).
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DISCUSSION
In a randomised clinical trial cohort of patients with locally
advanced HNSCC treated with high-dose cisplatin-radiotherapy
with or without erlotinib, ERCC1 protein expression level assayed
by the specific ERCC1 antibodies FL297 and 4F9 was prognostic:
patients with higher tumoural expression experienced significantly
inferior PFS. This relationship was significant both in proportional
hazards regression with ERCC1 defined as a continuous variable
and when the study population was divided into ‘increased’ vs
‘decreased/normal’ expression by a predefined binary cutpoint with
potential clinical utility. This conclusion is further strengthened by
prospective collection of clinical outcomes in the context of a
clinical trial, sample size, homogeneity of exposure to cisplatin and
radiotherapy, and concordant results from two specific ERCC1
antibodies. Similar to a recent retrospective series, the nonspecific
8F1 antibody was not found to be prognostic (Hao et al, 2011).
The ERCC1-XPF nuclease is the only DNA repair enzyme
critical to both NER and ICL repair, thus is an attractive candidate
biomarker for cisplatin resistance. The challenge in oncology has
been validation of a measurement technique that correlates with
DNA repair capacity, applies to available FFPE tissue specimens or
peripheral blood, and predicts a relevant clinical outcome. Aspiring
methodologies include single-nucleotide polymorphisms (SNPs) in
the ERCC1-XPF gene, quantification of tumoural ERCC1 mRNA,
and semi-quantitative ERCC1-XPF protein expression by IHC.
Although SNPs are appealing due to ease of acquiring germline
DNA through peripheral blood, no SNP has emerged as a
consistent predictor of HNSCC risk or treatment response (Vaezi
et al, 2011a). ERCC1 mRNA is measurable with RT–PCR in FFPE
specimens as a surrogate for ERCC1-XPF function and demon-
strates promise in tailoring platinum chemotherapy in advanced
NSCLC (Simon et al, 2012). However, because of post transcription
processing, ERCC1 mRNA does not consistently correlate with
protein expression(Britten et al, 2000; Zheng et al, 2007), and was
not associated with response or survival in HNSCC patients
undergoing cisplatin-radiotherapy (Hao et al, 2011). Because of
lack of correlation with prognosis in antecedent studies, ERCC1
SNPs and mRNA were not evaluated here.
In HNSCC, the most promising measurement technique for
predicting outcome from cisplatin-based therapy has been
expression level of ERCC1-XPF protein by semi-quantitative
IHC. Immunodetection faces several methodologic challenges
including geographic variation in protein expression within a
tumour (Taillade et al, 2007) pre-analytic variables such as
collection, tissue processing/fixation protocols, and storage (Babic
et al, 2010); and rates of interobserver agreement (Taylor and
Levenson, 2006). In HNSCC, clinical development of an ERCC1-
XPF biomarker also has been impaired by recognition of the non-
specificity of 8F1 (Niedernhofer et al, 2007), used in the majority of
early retrospective studies, and the inconsistent association of 8F1
with PFS. In the current study, we confirmed that 8F1 was not




















Black or African-American 16% 14%
































Table 2. Summary of marker prevalence






















Normal: 1.5 oH-scoreo2.5. Increased: H-score X2.5.
aDecreased: H-score p1.5.
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prognostic in a randomised study population treated homoge-
neously with cisplatin-radiotherapy and do not recommend this
antibody for further development. This recommendation is in line
with the recent contradiction of the original IALT findings in
NSCLC with 8F1 (Friboulet et al, 2013).
Another barrier to routine use of semi-quantitative IHC for
ERCC1-XPF protein expression is that an optimal cutpoint for
clinical classification has not been established. To date, retro-
spective studies commonly divided their population at the median
to compare outcomes for high vs low tumour expression. While an
illustrative technique, the median split from one study cohort may
not be reproducible or valid in a subsequent cohort. Further
challenging the movement of an ERCC1-XPF measurement
technique into the integral biomarker setting is validation of a
scoring methodology against a standardised control. In the current
study, evaluation of diagnostic FFPE tissue posed challenges
similar to the routine clinical setting. Patients were treated at eight
academic and community centers; variations in collection and
processing were assumed to influence ERCC1 immunodetection
and to be confounding. For this reason, we developed a standard
operating procedure using an internal control. We scored tumour
cells with reference to non-neoplastic basal epithelial cells,
assuming that pre-analytic variables influencing ERCC1 antigen
detection were identical for tumour and non-neoplastic cells
within the same specimen. Both specific antibodies were
prognostic using this methodology, strengthening confidence in
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Figure 3. Bland–Altman plots comparing H-scores for three ERCC1 assays. Mean differences were centered around zero for all assays (solid lines),
but 95% limits of agreement (dashed lines) were more narrow for the FL297 and 4F9 antibodies.
Table 3. Cox proportional hazard regression for ERCC1 expression by PFS
ERCC1 (FL297) N¼88 ERCC1 (4F9) N¼88 ERCC1 (8F1) N¼90
Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value
A. Continuous ERCC1 expression
Hazard ratio (e.g. H-score of 3 vs 2 or 2 vs 1) 2.5 (1.1–5.9) 0.03* 3.0 (1.2–7.8) 0.02* 1.4 (0.8–2.5) 0.21
B. ERCC1 expression categorised by pre-determined H-score cutpointsa
Hazard ratio
Normal/increased vs decreased 3.4 (0.4–25.9) 0.24 1.8 (0.4–8.1) 0.42 — —
Increased vs normal/decreased 4.8 (1.7–13.2) 0.003* 5.5 (1.6–18.9) 0.007* — —
C: Categorised ERCC1, also controls for p16 (p16-positive oropharyngeal tumour vs other)a
Hazard ratio
Normal/increased vs decreased 3.4 (0.4–25.5) 0.24 1.9 (0.4–8.3) 0.40 — —
Increased vs normal/decreased 4.6 (1.6–13.2) 0.004* 5.2 (1.5–18.3) 0.01* — —
Models were stratified by randomization strata (including N-stage) and controlled for treatment arm.
aExploratory analysis, excluding 8F1 antibody based on results of primary analysis (3A).
*Indicates statistical significance.
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Two validated and specific antibodies, FL297 against ERCC1
(Hao et al, 2011) and SPM228 against XPF (Vaezi et al, 2011b),
have been associated with PFS in small retrospective cohorts
undergoing platinum-radiotherapy. The FL297 antibody is specific
for ERCC1 and has been validated by multiple techniques














































































Figure 4. (A–C) Kaplan–Meier curves showing PFS as a function of categorical ERCC1. For the primary analysis, PFS was treated as a continuous
variable. For purposes of graphical display, PFS is presented in Figure 4 for each antibody, according to pre-defined categories of ERCC1
expression: increased (H-score X2.5), normal (1.5o H-score o2.5), or decreased (H-score p1.5). Hazard ratios are presented for the exploratory
cutpoint, ‘increased’ vs ‘normal/decreased’ ERCC1 expression as detected by the two specific antibodies. * Indicates statistical significance.
0.0
p16 negative p16 positive
























p16 negative p16 positive















Figure 5. Distribution of ERCC1 by p16 expression. Boxplots present ERCC1 expression by p16 status, for the specific antibodies FL297 and 4F9.
Plotting characters identify tumour site category (oropharyngeal vs non-oropharyngeal). * Indicates statistical significance.
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FL297 is the variable degree of cytoplasmic staining (so-called
‘cytoplasmic bleed’) occurring in both normal and ERCC1-XPF-
deficient cells (Bhagwat et al, 2009). Because scoring must be
restricted to the nucleus, the exclusive site of ERCC1-XPF function,
background cytoplasmic staining increases the difficulty of
interpretation. In this study, we simultaneously evaluated FL297
and the newly available 4F9 clone that demonstrated excellent
agreement and were similarly prognostic. However, the 4F9
antibody produced crisp nuclear staining with little to no
cytoplasmic bleed. Moreover, 4F9 is a monoclonal antibody, which
ensures consistent antigenicity and sustainable production over
time. As detailed experiments confirmed that 4F9 is also specific
for ERCC1, in line with a recent report of its ultra-specificity
(Ma et al, 2012), we recommend 4F9 for further development
based upon ease of clinical interpretation.
The primary analysis focused upon proportional hazards
regression with ERCC1 expression as a continuous variable.
We also explored two pre-specified cutpoints to facilitate future
clinical application: decreased/normal vs increased expression and
decreased vs normal/increased expression. Of note, the former
classification significantly distinguished patients with superior vs
inferior PFS, whereas the alternate classification did not. More
precisely stated, patients with greater ERCC1 protein expression in
tumour cells than adjacent normal basal epithelial cells demonstrated
inferior PFS. Of interest, this cutpoint also corresponded closely with
the median split, as utilised in retrospective reports (Hao et al, 2011;
Vaezi et al, 2011b). This cutpoint is clinically applicable and
prognostic with two specific antibodies. External validation and
investigation of inter-observer agreement are appropriate next steps.
This study has several limitations. First, although enrolled
prospectively onto a randomised trial and treated homogeneously
with cisplatin-radiotherapy, tissue was collected optionally and
available for only 90/204 patients (44%). Baseline characteristics
were largely similar in patients with or without submitted tissue,
with the exception that patients with oral cavity tumours were
unlikely to have available tissue. While the oral cavity is associated
with higher ERCC1-XPF expression than other mucosal sites
(Vaezi et al, 2011b), the study population included only 7.5% oral
cavity, in keeping with current guidelines favoring primary surgery
for oral cavity tumours (Ang et al, 2010). Consequently, presented
results are likely generalizable to the HNSCC population
recommended for cisplatin-radiotherapy. Second, the scoring
methodology required the presence of non-neoplastic basal
epithelial cells within the primary tumour specimen. Although all
submitted specimens met this requirement, the method would not
be applicable to tissue from lymph node or other metastases. Third,
the study population included both HPV-positive and -negative
disease, increasingly studied separately because of striking prog-
nostic differences (Ang et al, 2010). Because ERCC1 expression was
significantly associated with p16 status in this population,
a potential criticism is that ERCC1 expression was a mere proxy
for HPV status. However, restricting analysis to p16-positive orophar-
yngeal cases indicated that ERCC1 expression added additional
prognostic information in HPV-associated disease. Fourth, recent
characterisation of four ERCC1 isoforms in the A549 NSCLC cell
line indicated that only the ERCC1–202 isoform is functional in
repairing cisplatin damage (Friboulet et al, 2013). As no current
ERCC1 antibody is specific for this isoform, the authors challenge
the clinical utility of ERCC1 characterisation by IHC. Although
both FL297 and 4F9 detect the ERCC1–202 isoform, each detects
at least two other isoforms, which appear not to function in
repairing cisplatin DNA damage. Simultaneous detection of non-
functional isoforms creates potential for categorical misclassifica-
tion of tumour ERCC1 expression. Despite this acknowledged
limitation, ERCC1 expression by FL297 and 4F9 demonstrated
strong and concordant association with PFS in this study. The
prognostic association is robust, clinically meaningful and in line
with reports by others (Hao et al, 2011; Vaezi et al, 2011b).
We hypothesise that detection of ERCC1–202 underlies prognostic
performance; however, the biologic underpinnings of this clinical
association require further elucidation. Future methodologies for
specific detection of the ERCC1–202 isoform may prove to be
superior biomarkers of clinical cisplatin resistance.
In summary, baseline ERCC1-XPF protein expression by FL297
or 4F9 is prognostic of PFS in patients with locally advanced
HNSCC undergoing cisplatin-radiotherapy, irrespective of p16
status. The specific antibody 4F9 warrants further clinical develop-
ment as a prognostic biomarker, preferred over FL297 because of
staining characteristics and qualitative ease of intepretation.
The current study does not qualify ERCC1-XPF overexpression as
a predictive biomarker of cisplatin resistance, as all patients received
platinum. Investigating this hypothesis would require a randomised
trial with stratification by ERCC1-XPF expression status, comparing
cisplatin with a non-platinum alternative – such as docetaxel or
cetuximab which radiosensitise through ERCC1-independent
mechanisms (Huang et al, 1999; Milas et al, 1999). Such a trial
could be justified should our findings, including the candidate
cutpoint, be replicated in a separate cohort.
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